2017 Objectives & Accreditation

This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council
for Continuing Medical Education (ACCME) through the joint
providership of the University of Colorado School of Medicine and
Jackson Hole Seminars. The University of Colorado School of Medicine
is accredited by the ACCME to provide continuing medical education for
physicians.

The University of Colorado School of Medicine designates this live
activity for a maximum of 30.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent
of their participation in the activity.

  • Participants should be able to discuss the different risk factors for transitional cell carcinoma.
  • Differentiate between pan-urothelial disease initially from an upper tract source as opposed to a lower tract source.
  • Assess the disease for progression.
  • Participants should be able to describe the different methods of endoscopic treatment of ureteral strictures.
  • Differentiate between good risk and poor risk for success.
  • Determine what success is.
  • Participants should be able to describe the different approaches to treatments of stones of the upper urinary tract associated with obstruction.
  • Assess for postoperative obstruction following removal of the stone.
  • Differentiate between primary and secondary obstruction of the UPJ.
  • Participants should be able to discuss the role of neoadjuvant chemotherapy for high-stage upper tract TCC.
  • Determine which patients are most likely to benefit from neoadjuvant chemotherapy.
  • Differentiate between the benefits for high-grade and low-grade disease.
  • Discuss the use of chemotherapy advantages prior to surgery.
  • Participants should be able to discuss the endoscopic options for treatment of upper tract transitional cell carcinoma.
  • Describe the advantages and disadvantages of each of the endoscopic approaches.
  • Differentiate the disadvantages of the endoscopic approach.
  • The participants should be able to manage the index patient with BPH from initial presentation, initial evaluation, to surgical management.
  • Participants should be able to list modalities and identify surgical candidates based on the AUA guidelines for the management of BPH.
  • Participants should be able to identify risk factors for urinary adverse events after radiation or surgery for prostate cancer.
  • Participants should also be able to identify risk factors for anastomotic strictures after radical prostatectomy.
  • Participants should be able to identify patients at higher risk for urinary incontinence after surgery based on preoperative factors.
  • Participants should be aware of preoperative, intraoperative, and postoperative maneuvers that can result in improved urinary continence.
  • Participants should be aware of general practices that can improve outcomes after BPH surgery.
  • Participants should become aware of current simulation technology and the effects of surgical coaching on surgical outcomes.
  • Participants should be aware of issues related to urinary tract reconstruction in patients undergoing radical resection of non-gu canvcers.
  • Participants should also know the urinary functional effects of these resections.
  • Be able to discuss the implications of treatment and the order in which the two components of MUI are addressed.
  • Be able to describe the caveats that must be considered when determining the optimal treatment pathway for MUI.
  • Have tools to generate a plan and counsel patients on the risks and benefits of each step in the treatment of MUI.
  • Be familiar with the 2011 FDA safety communication and the partnered response from multiple pelvic floor professional societies and the rationale behind this response.
  • Be aware of alternatives to mesh reinforcement of pelvic prolapse repair
  • Be able to discuss the pros and cons of a variety of alternative pelvic floor reconstructive techniques, including NTRs and biologic grafts.
  • Discuss critical thinking when there is a discrepancy between the UDS and a patient’s presentation.
  • Discuss clinical scenarios in which UDS may not match patient symptoms.
  • Be familiar with current tools utilized to measure outcomes.
  • Be able to discuss the strengths and shortcomings of our currently available outcomes assessment tools.
  • Discuss potential adjunctive techniques to improve patient comprehension of and engagement in their treatment plan.
  • Discuss the effects of enhanced education on patient outcomes and quality of life in conjunction with 1st and 2nd line therapies for OAB (per the AUA/SUFU OAB clinical guidelines).
  • To better understand the urologists’ key role in management men with CRPC. To become familiar with the AUA’s CRPC guideline and its amendments
  • Understand the appropriate utilization for the currently available molecular tests for prostate cancer risk stratification.
  • Further understand the data supporting re-resection in patients with high-risk nonmuscle-invasive bladder cancer
  • Be familiar with the various definitions of biochemical failure after radiation for prostate cancer.
  • Understand the various success rates and complication rates of salvage treatment options after a man fails primary radiation therapy for prostate cancer.
  • Further the understanding of comparative effectiveness research in urology, by specifically examining the data supporting varying prostate cancer surgical treatment options.
  • Discuss anticipated risks of testosterone therapy and surveillance strategies to minimize potential harms
  • Review expected benefits of supplementation and thresholds warranting treatment
  • Understand limitations with available data on cardiovascular complications and among men with established or treated prostate cancer
  • Review the mechanism and indications for collagenase clostridium histolyticum in the treatment Peyronie’s disease
  • Discuss potential reasons for considering collagenase clostridium histolyticum as a first line therapy for Peyronie’s disease
  • Identify expected outcomes of surgical management of Peyronie’s disease
  • Discuss the most common clinical presentations of men with Peyronie’s disease
  • Review the most common age range, direction, and extent of curvature of men with Peyronie’s disease
  • Identify expected outcomes of Peyronie’s disease over time including pain, curvature change, and erectile dysfunction
  • Identify factors that place patients at high risk for dissatisfaction following placement of a penile prosthesis
  • Review methods to reduce the likelihood for patient dissatisfaction following surgery
  • Discuss the mechanisms of non-traditional testosterone supplementation, including selective estrogen receptor modulators and aromatase inhibitors
  • Review appropriate dosing of alternative forms of testosterone supplementation
  • Identify benefits and appropriate follow-up protocols for surveillance after initiating alternative forms of testosterone supplementation